Legacy Capital Wealth Partners LLC Buys New Shares in West Pharmaceutical Services, Inc. (NYSE:WST)

Legacy Capital Wealth Partners LLC purchased a new stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 655 shares of the medical instruments supplier’s stock, valued at approximately $216,000.

Other large investors have also recently bought and sold shares of the company. International Assets Investment Management LLC grew its stake in West Pharmaceutical Services by 13,230.0% during the fourth quarter. International Assets Investment Management LLC now owns 18,662 shares of the medical instruments supplier’s stock worth $6,571,000 after purchasing an additional 18,522 shares during the period. Benjamin F. Edwards & Company Inc. bought a new stake in shares of West Pharmaceutical Services in the 4th quarter valued at $429,000. Metis Global Partners LLC increased its stake in shares of West Pharmaceutical Services by 2.6% in the 4th quarter. Metis Global Partners LLC now owns 5,434 shares of the medical instruments supplier’s stock valued at $1,913,000 after acquiring an additional 138 shares in the last quarter. Private Advisor Group LLC lifted its position in shares of West Pharmaceutical Services by 16.4% during the 4th quarter. Private Advisor Group LLC now owns 1,634 shares of the medical instruments supplier’s stock valued at $575,000 after acquiring an additional 230 shares during the period. Finally, Lincoln National Corp boosted its stake in West Pharmaceutical Services by 17.2% during the fourth quarter. Lincoln National Corp now owns 2,114 shares of the medical instruments supplier’s stock worth $744,000 after acquiring an additional 310 shares in the last quarter. 93.90% of the stock is currently owned by institutional investors and hedge funds.

West Pharmaceutical Services Trading Up 0.2 %

WST opened at $304.72 on Thursday. The company has a market cap of $22.10 billion, a P/E ratio of 40.20, a price-to-earnings-growth ratio of 11.15 and a beta of 1.01. The company has a fifty day moving average price of $308.57 and a two-hundred day moving average price of $342.04. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services, Inc. has a 1-year low of $265.00 and a 1-year high of $413.70.

West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The firm had revenue of $702.10 million during the quarter, compared to the consensus estimate of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The business’s quarterly revenue was down 6.9% on a year-over-year basis. During the same period in the previous year, the firm earned $2.11 earnings per share. Analysts predict that West Pharmaceutical Services, Inc. will post 6.44 EPS for the current fiscal year.

Insider Transactions at West Pharmaceutical Services

In related news, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction on Monday, August 19th. The shares were sold at an average price of $300.00, for a total value of $308,700.00. Following the completion of the sale, the vice president now owns 1,478 shares of the company’s stock, valued at approximately $443,400. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, SVP Silji Abraham sold 1,800 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $330.78, for a total value of $595,404.00. Following the transaction, the senior vice president now owns 2,860 shares in the company, valued at $946,030.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Charles Witherspoon sold 1,029 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the sale, the vice president now owns 1,478 shares of the company’s stock, valued at approximately $443,400. The disclosure for this sale can be found here. 0.53% of the stock is owned by insiders.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.